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Randomised trials have established the importance of oxaliplatin (O) and irinotecan (I) in advanced colorectal cancer (CRC).
However, patients enrolled in clinical studies represent a restricted population and little is known about the use of O and I in the
general population and the subsequent outcomes outside clinical studies. We used the Australian Health Insurance Commission
(HIC) database to describe prescribing patterns of O and I and their impact on survival in all patients with 5-fluorouracil (5-FU)
refractory CRC in Australia in 2002 and 2003. In 2999 patients, there was a marked increase in initial treatment with O rather than I;
48% of patients received O first in 2002 vs 66% in 2003 (Po0.001). Overall 40–45% of patients received both O and I; however,
younger patients were more likely to receive both drugs (Po0.001). After 5-FU failure and treatment with O or I, the proportion of
patients surviving 6 or 12 months was estimated to be 0.67 (95% CI, 0.66–0.69) and 0.42 (95% CI, 0.40–0.44), respectively. Survival
was superior for patients who received both O and I; however, the sequence of agents had no impact. Older patients (X70 years)
had inferior survival no matter which drug was used as initial treatment. Analysis of the Australian HIC database provides a valuable
means of assessing patterns of use and outcomes of new therapies.
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Colorectal cancer (CRC) is the second most common cause of
cancer death in Australia. Approximately 40% of diagnosed
patients will ultimately die of the disease ((Australian Institute of
Health and Welfare (AIHW) and Australian Association of Cancer
Registries (AACR), 2004)).
Fluorouracil (5-FU) and its modulator leucovorin (LV) have
been used for the treatment of metastatic CRC for years. Irinotecan
(I), an inhibitor of topoisomerase I, was one of the first cytostatics
to show a survival benefit in the treatment of 5-FU-resistant
disease (Cunningham et al, 1998; Rougier et al, 1998). This was
confirmed in the first-line setting when irinotecan was combined
with either bolus (Saltz et al, 2000) or infusional (Douillard et al,
2000) 5-FU. A similar progression-free survival benefit was
achieved with the combination of the platinum analogue,
oxaliplatin (O), with 5-FU (De Gramont et al, 2000; Grothey
et al, 2002).
However, Grothey et al (2004) recently showed the importance
of making all active agents, 5-FU/LV, oxaliplatin and irinotecan,
available to patients during the course of their disease to achieve
optimal survival.
Although the benefit of I and O in the treatment of metastatic
CRC has been clearly established in clinical trials, few studies have
evaluated the use of these agents in the general population outside
clinical trials.
The Health Insurance Commission (HIC), now Medicare
Australia, is a Government organisation whose main task is to
provide to all Australian residents equity of medical care under
the state insurance scheme, Medicare, and to make a range of
necessary prescription medicines available at affordable prices
through the Pharmaceutical Benefit Scheme (PBS). This scheme
provides access to approved drugs for both public and private
patients as private health funds do not provide drug reimburse-
ment in Australia.
Given the expense of I and O and the funding arrangements
within the health system of Australia, almost all use of these drugs
by metastatic CRC patients in Australia is subsidised under the
PBS and thus recorded in the database. The PBS item numbers for
I and O are specific for metastatic CRC as they are not PBS
approved for other indications.
In this study, we have used the HIC database to describe trends
in prescribing patterns of oxaliplatin and irinotecan and to
evaluate survival outcomes analysed by treatment sequence and
patient demographics.
This analysis provides information about patterns of use of O
and I and estimates of survival for the general population of
Australian patients, rather than being restricted to the population
enrolled in clinical studies.
This means that these results may be of interest both within and
outside Australia, particularly as we are not aware of any reports of
comparable data for other countries.
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The research undertaken in this analysis was approved by Austin
Health Human Research Ethics Committee. The HIC database was
searched to identify the patients with metastatic CRC who had one
or more scripts for I or O supplied under the PBS between 1
January 2001 and 31 December 2004. For the period of this
analysis, I and O were approved under the PBS only for patients
with metastatic CRC who had failed 5-FU and LV. Thus, during
this time interval patients would generally receive PBS approval for
O or I as second- or third-line treatment of metastatic disease after
5FU failure. The cohort of patients followed was defined as those
patients who received their first supply (no supply of either agent
previously) of I or O between 1 January 2002 and 31 December
2003.
The following data were available for each patient: sex, age at 1
January 2002, date of first supply of I or O, state/territory of
supplier, region (city/country) of supplier and date of last supply
of any PBS item. The HIC summarised the patient-level data into
tables, which we analysed.
The proportion of patients whose first supply was I or O as well
as the proportion of patients switching from O to I and vice versa
was analysed using logistic regression to determine how this
proportion varied with year, sex, age group and location.
Exact date of death was not routinely recorded on the HIC
database. However, terminally ill patients are expected to require
regular PBS-approved medications such as nonsteroidal analgesics,
morphine derivates, sedatives, laxatives as well as medications for
other comorbid conditions. Ongoing supply of any PBS item
indicates ongoing survival of an individual patient, whereas
cessation of supply of PBS items was used in the analysis as a
surrogate indicator of death. Six- and 12-month survival was
estimated by calculating the proportion of patients with recorded
PBS prescriptions of any type at least 6 and 12 months after the
date of their first supply of either I or O.
The number of patients still alive at 6 and 12 months, as a
proportion of the number of patients who started a particular
treatment for metastatic CRC, was analysed using logistic
regression.
We have verified the validity of this surrogate marker of death
using a data set of 548 patients for whom the actual date of death
had been recorded. The median difference between the last date of
PBS supply and the actual recorded date of death was 7 days. For
patients with a recorded date of death, the estimated proportion of
patients still receiving PBS supplies (of any drug) 6 or 12 months
after the supply of I or O was within 2 percentage points of the




By searching the Australian HIC database, 1465 new patients with
5FU-refractory metastatic CRC starting either I- or O-based
chemotherapy were found in 2002 and 1534 in the year 2003.
These patients had no supply of I or O in 2001 and are therefore
likely to have been naı ¨ve to these agents. This is estimated to
represent approximately 90% of the population receiving these
agents as patients receiving these agents through the Repatriation
PBS (retired servicemen or women) (4% of prescriptions) and
patients receiving these agents in clinical trials would not be
identified with this analysis.
The proportion of male and female patients, the overall
age distribution and the age distribution for male and female
patients were similar in 2002 and 2003. Approximately 23% of
identified patients were 70 years and older and 2% were 80 years
and older.
Which treatment is used first?
There was a marked change to an earlier use of O in 5-FU
pretreated patients in 2003, as the overall percentage of patients
who were treated with O first was greater in 2003 than 2002 (66 vs
48%, Po0.001). The differences between 2002 and 2003 were
greater for younger than for older patients (Figure 1); however, it
was evident across all age groups. The change in the pattern of use
of I and O was observed consistently across all states in Australia.
How many patients started on I switch to O?
The overall percentage of patients switching from I to O was the
same for both years (45%). However, this percentage was greater
for younger than for older patients (Po0.001) (Table 1a), which
could be because more intensive treatments are usually prescribed
to younger and fitter patients. A similar pattern was observed in
both 2002 and 2003 and for male and female patients.
How many patients started on O switched to I?
Of the 697 patients who started O in 2002, 40% switched to I. This
percentage was the same in 2003. Similar to the previous
observation with I, this percentage was greater for younger than
for older patients (Table 1b).
Survival of patients
Of the 2999 patients who had their first supply of either I or O in
2002 or 2003, 2024 were known to be still alive 6 months after the
first supply of their respective treatment. The proportion of
patients surviving at 6 months was therefore estimated to be 0.67
(Table 2a).
At 12 months, 1262 were still alive with the estimated proportion
of patients surviving at 12 months being 0.42 (95% CI, 0.40–0.44).
The patients first supplied with O had 6- and 12-month survival, 4
percentage points higher than the patients first supplied with I
(each Po0.05; Table 2a). This difference is statistically significant,
but may reflect differences in the baseline characteristics of the
patients.
The largest difference in survival was observed between the
patients who received both O and I and those who received one
treatment only (Po0.001; Table 2b). However, for patients
who received both O and I, there was no difference in survival
according to treatment sequence (I-O vs O-I). The greater
survival in patients receiving both drugs sequentially might
reflect the fact that patients who have better prognosis disease or






















































Figure 1 New I or O patients first supplied with O, by age group and
year (*Po0.001; 2003 vs 2002 and young vs old).
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sthree lines of treatment as opposed to patients with worse disease
prognosis.
In contrast to these results, survival estimates from the time of
initiation of the last treatment were very similar, irrespective of the
agent and whether one or both agents had been used. Thus, when
the last treatment was O, 6- and 12-month survival proportions
were 0.55 and 0.30 for patients who received only O and were 0.55
and 0.25 for patients who had received prior I. Overall, the
proportions surviving 6 months was 0.46 when the last treatment
received was I only and 0.5 when the last treatment was I preceded
by O. The corresponding 12-month survival proportions were 0.25
and 0.22, respectively.
Thus, patients have a similar chance of survival after the last
treatment with either O or I, irrespective of prior treatment
sequence or number of prior agents.
Age and sex
Six- and 12-month survival after initial or treatment only with
either I or O varies with sex and age group. Higher survival was
observed in younger patients irrespective of the type of treatment.
Higher survival for younger male than female patients was
observed when the initial treatment was I. There was less
difference in survival between male and female patients when the
initial treatment was O.
DISCUSSION
The value of I or O in the treatment of either 5-FU-pretreated or
chemotherapy-naı ¨ve patients with metastatic CRC has been well
established in randomised clinical trials. Both drugs showed near-
identical response rates, progression-free and overall survival
times when they were combined with infusional 5-FU and when
directly compared (Tournigand et al, 2004; Colucci et al, 2005).
Staged sequencing of I and O-based regimens can achieve median
survival times of approximately 20 months in patients with
metastatic CRC (Tournigand et al, 2004).
However, patients in clinical trials represent a restricted
population. They are usually younger, fitter, and without
comorbidities, which could potentially influence the outcomes.
There are no published data on the use of modern treatments in
metastatic CRC in the general population.
This study analyses patterns of use of I and O in Australia over a
period of 2 years. During that time, both drugs were approved only
for metastatic CRC patients who had failed initial 5-FU-based
treatment.
Searching the Australian HIC database, 2999 patients with 5-FU
refractory metastatic CRC were found to receive initial treatment
with either I- or O-based regimen in the years 2002 and 2003,
which is roughly two-thirds of all patients expected to be treated
for metastatic disease. The remaining one-third of patients was
likely to receive either single-agent 5-FU or palliative care only.
These estimates are based on the observations that approximately
15–20% of all patients diagnosed with CRC receive palliative
chemotherapy for their metastatic disease each year in Australia
(Spigelman and McGrath, 2000; McLeish et al, 2002). That is about
1900–2600 patients, taking into account 12900 patients newly
diagnosed with CRC in the year 2001 ((Australian Institute of
Health and Welfare (AIHW) and Australian Association of Cancer
Registries (AACR), 2004)).
Demographic trends
The distribution by age and sex was similar for both years.
Although patients aged X70 years account for 55% of newly
diagnosed CRC cases in Australia ((Australian Institute of Health
and Welfare (AIHW) and Australian Association of Cancer
Registries (AACR), 2004)), in our cohort only 23% of patients
receiving treatment were age 70 or older. However, the proportion
of older patients receiving treatment with I or O off-study is
greater than that typically observed in clinical trials in either
adjuvant (Sargent et al, 2001) or metastatic settings (Folprecht
et al, 2004). This is largely owing to the lack of appropriate trials, a
higher number of comorbidities, study-imposed restrictions, and
attitudes of physicians, although clinical data demonstrate that age
alone is not a sufficient reason to withhold treatment (Aapro et al,
2005).
Patterns of use of I and O
After failing 5-FU, 48% of patients in our cohort received an
O-based regimen first in the year 2002 and 66% in 2003. This is
probably a reflection of an increased trend for earlier use of O over
I in 5-FU-pretreated metastatic CRC after the results of N9741, the
Table 1a New I patients switching to O, by sex, age group and year of
starting I (percent and overall proportion)
New patients in 2002 New patients in 2003
Age group Male (%) Female (%) Male (%) Female (%)
o50 58 55 55 48
5 9 – 5 95 25 35 25 8
60–69 43 35% 45 45
7 0 – 7 94 43 33 82 6
X80 27 29 17 100
Overall 45 (344/768) 45 (234/525)
I, irinotecan; O, oxaliplatin.
Table 1b New O patients switching to I, by sex, age group and year of
starting O (percent and overall proportion)
New patients in 2002 New patients in 2003
Age group Male (%) Female (% Male (%) Female (%)
o50 46 46 53 55
50–59 45 37 43 41
60–69 45 36 42 37
70–79 34 30 29 24
X80 25 0 100 18
Overall 40 (276/697) 40 (401/1009)
I, irinotecan; O, oxaliplatin.
Table 2a Proportion of patients alive at 6 and 12 months after receiving
I or O as initial treatment
Either
I or O First supply I First supply O
Proportion alive at 6 months 0.67 0.65 0.69
Proportion alive at 12 months 0.42 0.40 0.44
I, irinotecan; O, oxaliplatin.
Table 2b Proportion of patients alive at 6 and 12 months after receiving
either I or O alone or both agents as sequenced treatments
I only O only I then O O then I
Proportion alive at 6 months 0.46 0.55 0.89 0.91
Proportion alive at 12 months 0.25 0.30 0.58 0.61
I, irinotecan; O, oxaliplatin.
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sNorthern Central Cancer Treatment Group trial, had been
reported.
In this phase III trial, the overall survival and toxicity profile
favoured first-line O (FOLFOX4) over the I combination (IFL).
These results may have been due to the fact that 60% of patients in
the FOLFOX4 arm received I on progression compared with only
24% receiving second-line O in the IFL arm. In addition, there was
also a possibility that the infusional 5-FU in the FOLFOX4 arm
may have been more effective than the bolus 5-FU in the IFL
regimen (Goldberg et al, 2004). In spite of those reservations,
O-based regimens have been adopted as the preferred first-line
regimen for the treatment of metastatic CRC in the USA. It seems
likely that this study has also influenced Australian practice.
Interestingly, the trend to use O earlier was observed consistently
across all states in Australia.
Grothey et al (2004), in a pooled analysis of recently published
phase III trials, highlighted the importance of sequencing of 5-FU,
I, and O in the treatment of metastatic CRC. They found a strong
correlation between reported median survival and the percentage
of patients who received all three available drugs.
In our 5-FU-pretreated population, the overall percentage of
patients switching from an I- to an O-based regimen was 45% in
both 2002 and 2003. In both years, 40% of patients receiving
second-line O subsequently switched to third-line I.
These switch rates are comparable with those observed in the
recently reported American N9841 phase III trial with a similar
study population to ours. In this study, patients who previously
failed 5-FU were first randomised to receive either 3-weekly I or 2-
weekly FOLFOX4 then crossed over to the other regimen at disease
progression. Fifty-one percent of patients receiving second-line I
switched to third-line FOLFOX4 and 38% of patients starting
FOLFOX4 subsequently received third-line I (Rowland et al, 2005).
Irrespective of the treatment sequence, in our study, the switch
rates were higher for younger than for older patients (Po0.001),
which could be the result of a better performance status of the
younger population or a tendency to treat older patients less
intensively.
Survival outcomes with different types of treatment and
treatment sequences
In the Australian population, estimated 6- and 12-month survival
after 5FU failure was 66 and 40% in 2002 and 69 and 44% in 2003,
respectively. The differences in survival between 2002 and 2003
were not statistically significant. When survival was analysed by
the first treatment supplied, patients who received O first appeared
to have both better 6-month (69 vs 65%, Po0.05) and 12-month
survival (44 vs 40%, Po0.05) compared with patients receiving I
first after 5-FU failure. As this is a non-randomised comparison,
these differences in survival observed in our study may reflect
different patient baseline characteristics.
Six and 12-month survival rates for second-line O or I in our
study were slightly lower but similar to the ones reported in
clinical trials (Table 3), which probably reflects the fact that the
patients enrolled in clinical trials are usually younger and fitter
with fewer comorbidities than the ones treated outside clinical
trials. Thus, the use of second-line I after 5-FU failure in clinical
studies was associated with 6- and 12-month survival rates ranging
from 70 to 80% and 41 to 57%. The corresponding 6- and 12-
month survival rates after second-line O ranged from 82 to 83%
and 57 to 60% (Table 3).
In accordance with Grothey’s analysis (Grothey et al, 2004),
those 5-FU refractory patients who received both I and O during
the course of their treatment, irrespective of the treatment
sequence, had the longest 6- and 12-month survivals (89–91 and
58–64%, respectively). Although likely to be at least partly
explained by a treatment effect, this result is confounded by the
fact that patients with less aggressive disease are able to live long
enough to be able to receive all available agents.
Influence of age and sex on survival
We found higher survival for younger patients irrespective of the
type of initial treatment, perhaps because clinicians treat older
patients less intensively.
This is contrary to the observations from randomised clinical
trials, which showed similar efficacy and toxicity rates for 5-FU, I
or O in selected older patients (X70 years) compared with younger
patients (Botto, 2004; Folprecht et al, 2004; Stewart et al, 2004;
Goldberg et al, 2006).
CONCLUSIONS
In conclusion, this study shows the feasibility of the analysis of the
HIC database for evaluation of prescribing trends and treatment
outcomes in real practice.
As anticipated, the survival rates observed in the general
population after the use of I and O are not as high as those
observed in prospective randomised clinical studies. Nevertheless,
these data provide important information about realistic outcomes
that may be achieved with these agents.
It is reassuring that many outcomes from this study are similar
to observations from prospective clinical trials, indicating that
these results are generalisable. For instance, our study shows the
importance of making all three active agents (5-FU, I and O)
available to metastatic CRC patients in order to achieve maximum
benefit. Similarly, there was no clear indication that any particular
sequence of agents is preferable.
Table 3 Survival of 5-FU refractory pts treated with either O or I in clinical trials
Overall survival
6-month (%) 12-month (%) Median (months)
Study I O I O I O P-value
Second-line
(Fuchs et al, 2003) 70 — 41 — 9.9 —
(Maughan, 2005) 80 83 57 60 14.8 15.2 NS
(Haller et al, 2004) 73 82 (I+O) 48 57 (I+O) 11.1 13.4 (I+O) 0.0072
Third-line
(Rowland et al, 2005) 71 75 35 39 8.7 10 NS
I, irinotecan; NS: nonsignificant; O, oxaliplatin.
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sThe general population also includes older patients and patients
with comorbidities who are frequently excluded from clinical
trials. In spite of the availability of these drugs to all patients, the
older population in real life is less likely to be treated with both I
and O. Contrary to observations from clinical trials with highly
selected older patients, their survival outcomes appear worse
compared with younger age groups. This is likely to be due to
generally worse performance status and a larger number of
comorbid conditions.
Newer biological agents including bevacizumab and
cetuximab have now shown benefits in clinical trials in advanced
CRC. These agents have not yet received PBS approval in Australia.
However, if they were to receive approval in the future, we
believe that a similar analysis to this would be valuable to
define the benefits associated with these agents in the general
population.
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